Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Eur Urol. 2019 Jul 18;76(6):754–764. doi: 10.1016/j.eururo.2019.06.015

Table 1 –

Hereditary renal cell carcinoma syndromes

Gene Syndrome Histology Selected associated extrarenal
clinical features
Example initial screening recommendations
VHL von Hippel-Lindau ccRCC
Clear cell papillary
• Retinal and CNS haemangioblastomas
• Pancreatic cysts and neuroendocrine tumours
• Endolymphatic sac tumour
• Pheochromocytoma
• Others
Renal:
• Annual abdominal ultrasound
• MRI of abdomen every 2 yr 28620007
Other:
• Ophthalmological exam
• Blood pressure check and neurological assessment
• Audiology assessment
• Plasma-free metanephrines/urinary metanephrines
• MRI of brain and cervical spine
FH Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) HLRCC-associated RCC
Papillary type 2
Others
• Cutaneous leiomyomas
• Uterine leiomyomas
• Leiomyosarcomas
Renal:
• Annual MRI with renal protocol 28620008
Other:
• Dermatological exam
Gynaecological exam for women
FLCN Birt-Hogg-Dubé Chromophobe
Oncocytoma
Hybrid
Clear cell
• Fibrofolliculomas and other skin findings
• Renal and lung cysts
Renal:
• CT or MRI of abdomen every 3 yr 23703644
Other:
• CT of the chest
• Dermatological exam
MET Hereditary papillary renal cell carcinoma Papillary type 1 • None Renal:
• Renal ultrasound every 2 yr
Other:
• None
TSC1/TSC2 Tuberous sclerosis Angiomyolipoma
ccRCC
cystic oncocytoma
• Angiomyofibromas and other dermatological lesions
• Cortical dysplasia
• Subependymal giant cell astrocytoma
• Lymphangioleiomyomatosis
• Others
Renal:
• MRI of abdomen every 1–3 yr 24053983
Other:
• Dermatological exam
• Dental exam
• Ophthalmological exam
• Assessing renal function and blood pressure yearly
• Screening neuropsychiatric disorders
• Brain MRI
• Routine EEG by clinical indication
• ECG
• CT of the chest every 5–10 yr for asymptomatic patients
BAP1 BAP1 tumour predisposition syndrome Undefined • Uveal and cutaneous melanomas
• Mesothelioma
Renal:
• CT or MRI of abdomen every 2 yr 29413689
Other:
• Ophthalmological exam
• Dermatological exam
• Consider CT or MRI of chest/abdomen
SDHA/B/C/D Hereditary paraganglioma-pheochromocytoma syndromes SDH-deficient RCC • Paragangliomas
• Pheochromocytoma
• GIST
Renal:
• Abdominal MRI every 2 yr 28620007
Other:
• Blood pressure
• Plasma methoxytyramine, PFM/urine metanephrines
• Serum chromogranin A
• Complete blood counts
• Whole-body MRI (skull base of pelvis)
MITF MITF predisposition to familial RCC Undefined • Melanoma Renal:
• Renal ultrasound every 1–2 yr
Other:
• Dermatological exam
PTEN Cowden syndrome Papillary
Chromophobe
ccRCC
•Dermatological lesions
• Breast cancer
• Thyroid cancer
• Endometrial cancer
• Others
Renal:
• Renal ultrasound every 1–2 yr 28040716
Other:
• Thyroid exam
• Dermatological exam
• Breast exam, mammogram and breast MRI (women)
• Thyroid ultrasound
• Colonoscopy
• Consider endometrial cancer screening (women)
CDC73 Hyperparathyroidism jaw tumour syndrome Renal cysts
Renal hamartomas
Wilms tumours
Other
• Primary hyperparathyroidism
• Ossifying fibromas of the mandible or maxilla
• Parathyroid carcinoma
• Uterine tumours
Renal:
• Renal ultrasound at least every 5 yr 20301744
Other:
• Serum calcium, intact parathyroid hormone, and 25-(OH) vitamin D levels
• Dental panoramic X-ray with neck shielding
• Screening for uterine tumours (women)

ccRCC = clear cell RCC; CNS = central nervous system; CT = computed tomography; ECG = electrocardiography; EEG = electroencephalography; GIST = gastrointestinal stromal tumour; MRI = magnetic resonance imaging; PFM = plasma-free metanephrine; RCC = renal cell carcinoma; SDH = succinate dehydrogenase.

Summary of the known syndromes, genetic alterations, associated histology, and selected associated extrarenal features is given. Example initial screening and surveillance recommendations are also provided.

*

Renal screening recommendations are applicable for initial screening. If a renal tumour or an abnormality is found, then imaging interval and modality should be determined by the treating provider.